Lactate dehydrogenase/albumin ratio predicts progression of disease within 24 months (POD24) in advanced-stage extranodal natural killer/T cell lymphoma
Authors:
Open Access
- 19 May 2026
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (7)
Abstract
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive malignancy with poor outcomes in advanced-stage disease. Although progression of disease within 24 months (POD24) serves as a powerful predictor of poor survival in various lymphoma subtypes, its utility in advanced-stage ENKTL has not been specifically validated. This study aims to identify high-risk patients with advanced-stage ENKTL and determine the clinical factors associated with early recurrence following anti-tumor treatment. We retrospectively analyzed 119 patients with advanced-stage ENKTL. All patients received asparaginase-based chemotherapy. Of the 119 patients, 81 patients (68.1%) experienced POD24. The 5-year overall survival (OS) rate was 36.0% for the entire cohort. Patients with POD24 had significantly worse outcomes compared to non-POD24 patients (5-year OS: 10.6% vs. 81.4%; p < 0.001). The optimal thresholds for serum albumin (ALB) and lactate dehydrogenase (LDH) levels were identified as 35.5 g/Land 264 u/L, respectively, and 6.0 for lactate dehydrogenase/albumin ratio (LAR). The result identified Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2, LDH >264 u/L, ALB 6.0, lymphocyte count 6.0 is a readily available biomarker for predicting POD24, independent of EBV-DNA status. These findings facilitate early risk stratification and may guide treatment intensification strategies in this population.Keywords
This publication has 24 references indexed in Scilit:
- A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginaseFuture Oncology, 2024
- Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphomaHematology, 2023
- Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) studyLeukemia, 2020
- Evaluation of prognosis following early disease progression in peripheral T-cell lymphomaInternational Journal of Hematology, 2020
- Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectThe Lancet Haematology, 2020
- The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United StatesCancer, 2017
- Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European CasesCurrent Hematologic Malignancy Reports, 2016
- A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysisThe Lancet Oncology, 2016
- Serum albumin: Accuracy and clinical useClinica Chimica Acta, 2013
- Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphomaLeukemia & Lymphoma, 2009